

Alan L Ho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5690942/publications.pdf>

Version: 2024-02-01

65
papers

8,994
citations

136950

32
h-index

110387

64
g-index

65
all docs

65
docs citations

65
times ranked

14698
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
2	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
3	Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 623-632.	27.0	692
4	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010, 42, 715-721.	21.4	642
5	Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. <i>Lancet Oncology</i> , The, 2011, 12, 815-824.	10.7	311
6	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	30.7	282
7	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	1.6	239
8	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
9	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	7.1	191
10	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 371-382.	10.7	171
11	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	3.6	165
12	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	7.0	153
13	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
14	Consistent <i>PLAG1</i> and <i>HMGA2</i> abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. <i>Human Pathology</i> , 2015, 46, 26-33.	2.0	103
15	Sustained ERK inhibition maximizes responses of <i>BrafV600E</i> thyroid cancers to radioiodine. <i>Journal of Clinical Investigation</i> , 2016, 126, 4119-4124.	8.2	102
16	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	1.6	100
17	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	6.3	98
18	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	5.2	95

#	ARTICLE	IF	CITATIONS
19	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. <i>Radiotherapy and Oncology</i> , 2011, 101, 425-430.	0.6	88
20	Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780. <i>Molecular Biology of the Cell</i> , 2009, 20, 2218-2228.	2.1	87
21	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	12.8	77
22	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	7.0	75
23	Androgen Receptor Signaling in Salivary Gland Cancer. <i>Cancers</i> , 2017, 9, 17.	3.7	69
24	PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma. <i>Cancer Research</i> , 2012, 72, 4515-4525.	0.9	68
25	Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype. <i>PLoS ONE</i> , 2012, 7, e40439.	2.5	63
26	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. <i>Cancer Research</i> , 2018, 78, 4642-4657.	0.9	60
27	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. <i>Cancer</i> , 2017, 123, 4114-4121.	4.1	59
28	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021, 11, 1158-1175.	9.4	57
29	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 564-570.	0.8	51
30	The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. <i>Histopathology</i> , 2019, 75, 672-682.	2.9	43
31	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	2.0	41
32	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNP3-ALK rearrangement. <i>Human Pathology</i> , 2019, 88, 66-77.	2.0	38
33	Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. <i>Cancer</i> , 2020, 126, 2153-2162.	4.1	38
34	Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy. <i>Journal of Skin Cancer</i> , 2014, 2014, 1-7.	1.2	37
35	Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. <i>Cancer</i> , 2020, 126, 3972-3981.	4.1	34
36	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?. <i>Radiology and Oncology</i> , 2014, 48, 56-61.	1.7	30

#	ARTICLE	IF	CITATIONS
37	Novel Approaches to Thyroid Cancer Treatment and Response Assessment. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 109-118.	4.6	30
38	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. <i>Thyroid</i> , 2022, 32, 273-282.	4.5	30
39	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). <i>Journal of Clinical Oncology</i> , 2022, 40, 1870-1878.	1.6	29
40	The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind" A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. <i>Cancer</i> , 2020, 126, 4092-4104.	4.1	24
41	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 4.	6.2	19
42	Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. <i>NMR in Biomedicine</i> , 2020, 33, e4166.	2.8	19
43	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
44	Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. <i>Tomography</i> , 2020, 6, 129-138.	1.8	14
45	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2022, 20, 45-55.	3.4	13
46	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017, 35, 742-750.	2.6	10
47	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. <i>Endocrine-Related Cancer</i> , 2021, 28, 391-402.	3.1	10
48	Sex disparities in salivary malignancies: Does female sex impact oncological outcome?. <i>Oral Oncology</i> , 2019, 94, 86-92.	1.5	7
49	Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. , 2019, , .		7
50	Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 32-41.	0.3	7
51	ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. <i>Modern Pathology</i> , 2022, 35, 895-902.	5.5	7
52	Long-term quality of life in older patients with HPV-related oropharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 2321-2328.	2.0	6
53	Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic Features. <i>Head and Neck Pathology</i> , 2022, 16, 612-620.	2.6	6
54	A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. <i>Investigational New Drugs</i> , 2014, 32, 549-554.	2.6	5

#	ARTICLE	IF	CITATIONS
55	Unmet needs for patients with salivary gland cancer. <i>Oral Oncology</i> , 2016, 60, 142-145.	1.5	5
56	Androgen Receptor Pathway in Salivary Gland Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 4069-4072.	1.6	5
57	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. <i>Cancer</i> , 2019, 125, 2984-2990.	4.1	4
58	Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. <i>Oral Oncology</i> , 2022, 128, 105806.	1.5	4
59	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	4.5	4
60	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. <i>Journal of Radiation Oncology</i> , 2013, 2, 285-291.	0.7	3
61	Moving toward a better understanding of radioiodine action. <i>Endocrine</i> , 2013, 44, 553-554.	2.3	3
62	Challenges and Opportunities for Developing New Therapeutics for Salivary Gland Cancers. <i>Journal of Oncology Practice</i> , 2018, 14, 109-110.	2.5	3
63	Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11-year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts. <i>Head and Neck</i> , 2021, 43, 2497-2509.	2.0	2
64	Any day, split halfway: Flexibility in scheduling high-dose cisplatin—A large retrospective review from a high-volume cancer center. <i>International Journal of Cancer</i> , 2021, 149, 139-148.	5.1	1
65	Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 952-961.	1.7	1